A Phase 2 interventional study of NDI-034858 and Placebo in Psoriatic Arthritis, sponsored by Takeda. Completed at 56 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-31.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 69th largest by enrollment of the 158 interventional ones that give a count, is one of 11 that started in 2022, is one of 31 in phase 2, and was the 140th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 305 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 158 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 193 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 5 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 16 to your calendar (.ics) → With an account.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).
This is a Phase 2b, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Multiple Dose Study.
Randomization to one of the treatments with NDI-034858 Dose 1, 2, 3 or placebo once daily (QD) will be based on a 1:1:1:1 scheme.
The maximum study duration per participant is approximately 20 weeks, including up to 30 days for the screening period, a 12-week treatment period, and a 4-week safety follow-up period.
Efficacy will be assessed using the ACR20 composite measure (including tender and swollen joint count, patient assessment of PsA pain visual analog scale (VAS), patient global PsA assessment VAS, physician global PsA assessment, HAQ-DI, and hsCRP) as well as the additional components. Efficacy for psoriasis among participants who have ≥ 3% BSA) involvement on Day 1, will be measured using PASI, PGAs, and BSA.
Safety will be assessed by collecting AEs, recording vital signs, performing physical examinations, and evaluating clinical laboratory and ECGs results.
Blood samples will be collected to measure plasma concentrations of NDI-034858.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo capsules, orally, QD for 12 weeks.
Other: Placebo
Participants received NDI-034858 low dose, capsules, orally, QD for 12 weeks.
Drug: NDI-034858
Participants received NDI-034858 medium dose, capsules, orally, QD for 12 weeks.
Drug: NDI-034858
Participants received NDI-034858 high dose, capsules, orally, QD for 12 weeks.
Drug: NDI-034858
NDI-034858 oral capsule
Also known as: TAK-279
NDI-034858-matching oral placebo capsule
Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12
ACR20 is composite measure defined as improvement of 20 percent(%) from baseline in both number of tender (68) \& number of swollen (66) joints \& a 20% improvement in at least 3 of following 5 criteria: patient global assessment of psoriatic arthritis (PGA-PsA) \[visual analog scale (VAS) where, 0=very good, no symptoms \& 100=very poor, severe symptoms\], physician global assessment of psoriatic arthritis (PhGA-PsA) \[(VAS) where 0=no disease activity \& 100=maximum disease activity\], patient global assessment of psoriatic arthritis pain (PGAAP) \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire i.e., Health Assessment Questionnaire-Disability Index \[HAQ-DI\] (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip \& activities, 0=without difficulty to 3=unable to do) \& acute phase reactant like high sensitivity C-reactive protein \[hsCRP\]). Percentages are rounded off to the nearest decimal.
Time frame: Week 12
Percentage of Participants Who Achieved at Least an ACR-50 Response at Week 12
The ACR-50 is a composite measure defined as improvement of 50% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 50% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \[(VAS) where 0=no disease activity and 100=maximum disease activity\], PGAAP \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire (i.e., HAQ-DI) \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\] and an acute phase reactant \[i.e., erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\]. Percentages are rounded off to the nearest decimal.
Time frame: Week 12
Percentage of Participants Who Achieved at Least an ACR-70 Response at Week 12
The ACR-70 is a composite measure defined as improvement of 70% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 70% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \[(VAS) where 0=no disease activity and 100=maximum disease activity\], PGAAP \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire (i.e., HAQ-DI) \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\] and an acute phase reactant (i.e., ESR or CRP). Percentages are rounded off to the nearest decimal.
Time frame: Week 12
Change From Baseline in Tender Joint Count (TJC) at Week 12
The TJC 68 is a total score of points assigned for the presence of tenderness in the 68 joints in the upper body and upper/lower extremity. The response to tenderness for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all tender joints was derived. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 12
Change From Baseline in Swollen Joint Count (SJC) at Week 12
The SJC 66 (TJC 68 joint assessment minus hip joints, which cannot be assessed for swelling) is a total score of points assigned for presence of swelling in the 66 joints in the upper body and upper/lower extremity. The response to swelling for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all swollen joints was derived. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 12
Change From Baseline in PGA-PsA at Week 12
Participants assessed their overall disease status based on symptoms of psoriasis and psoriatic arthritis at the time of the visit using the PGA-PsA VAS of 100 millimeters (mm) which ranges from 0 (very good, no symptoms) to 100 (very poor, severe symptoms). A negative change from Baseline indicates improvement in symptoms.
Time frame: Baseline, Week 12
Change From Baseline in PGAAP at Week 12
Participants assessed their overall psoriatic arthritis-related pain at the time of the visit using the PGAAP VAS of 100 mm which ranges from 0 (no pain) to 100 (most severe pain). A negative change from Baseline indicates improvement in pain.
Time frame: Baseline, Week 12
Change From Baseline in PhGA-PsA at Week 12
The participants' overall disease status was assessed, taking into account signs, symptoms, and function, of all components of joint and skin affected at the time of the visit and this overall status was rated by the investigator using the PhGA-PsA VAS of 100 mm where 0 is 'very good, asymptomatic, and no limitation of normal activities' and 100 is 'very poor, very severe symptoms which are intolerable, and inability to carry out all normal activities'. A negative change from Baseline indicates improvement in symptoms.
Time frame: Baseline, Week 12
Change From Baseline in HAQ-DI Total Score at Week 12
The HAQ-DI consists of 20 questions referring to eight domains consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 (without any difficulty) to 3 (unable to do). The worst score within each domain will be used as the domain score (i.e., if the score for one question is 1 and 2 for the other, then the worst score for the domain is 2). The HAQ-DI total score is calculated by dividing the sum of the domain scores by the number of non-missing domains. The total score indicates the patient's self-assessed level of functional ability and higher scores indicate worse functional ability. The HAQ-DI total score ranges from 0 to 3. A higher score indicates worse function and greater disability. A negative change from Baseline indicates improved function.
Time frame: Baseline, Week 12
Change From Baseline in Dactylitis Count (DC) at Week 12
Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of total score. DC equals the number of tender fingers and toes (tender score \>0). For participants with dactylitis status absent for all the fingers and toes, the DC is set as 0. The total score range of DC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 12
Change From Baseline in Leeds Enthesitis Index (LEI) at Week 12
Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites, divided by the number of sites with non-missing score. The total score ranges from 0 to 6, higher scores indicate greater degree of enthesitis. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 12
Percentage of Participants With Minimal Disease Activity (MDA) Response at Week 12
MDA is a measure to indicate a state of minimal disease activity, and is a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC 68 ≤1; SJC 66 ≤1; Psoriasis area and severity index (PASI) score ≤1 \[The total score ranges from 0 (no disease) to 72 (maximal disease)\] or body surface area (BSA) ≤3%; PGAAP ≤15 \[using VAS on a scale of 0 (no pain) to 100 (serious pain)\]; PGA-PsA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1. Percentages are rounded off to the nearest decimal.
Time frame: Week 12
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 12
The DAPSA score is a composite score and was calculated using: TJC68, SJC66, PGA-PsA, PGAAP, and hsCRP level (milligram per deciliter \[mg/dL\]). DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. The DAPSA score has a lower bound of 0 and has no upper bound. A higher DAPSA score indicated more active disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 12
Percentage of Participants Who Achieved PASI-75 Response at Week 12
PASI-75 is assessed in participants with psoriasis involvement for ≥ 3% of the BSA at Baseline and assesses the extent of involvement and severity of psoriasis. To calculate the PASI, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI-75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease. Percentages are rounded off to the nearest decimal.
Time frame: Week 12
Percentage of Participants Who Achieved a Physician Global Assessment of Psoriasis (PhGA-PsO) of 0 or 1 and at Least a 2-point Improvement at Week 12
PhGA-PsO responder is defined as participants 1) who had PhGA-PsO score of 0 or 1 at any given post-baseline visit; and 2) who had at least 2-point improvement from baseline. The PhGA-PsO is measured using a 0 to 4 scale with a 0 meaning clear or a 4 meaning severe. The proportion of participants achieving PhGA-PsO response at Week 12 was calculated and analyzed for participants with a score of at least 2 at baseline. Percentages are rounded off to the nearest decimal.
Time frame: Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Adverse Event(AE)=medical occurrence that does not necessarily have a causal relationship with this drug also including clinically meaningful findings in laboratory safety tests,vital signs,weight,and electrocardiogram(ECG).TEAEs=AEs occurring at time of or post study drug dosing until study end.SAE=any medical occurrence at any dose that resulted in death,was life-threatening,required inpatient hospitalization/prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was a congenital abnormality/birth defect,an important medical event.AESIs included Common Terminology Criteria for Adverse Events(CTCAE)Grade≥2 cytopenia,CTCAE Grade≥3 elevation of creatine phosphokinase(CPK)\[clinically significant or not\]defined as CPK\>5xupper limit of normal(ULN),infections,adverse events of abnormal liver function tests,adverse events of renal dysfunction,major adverse cardiovascular events,thromboembolic events,gastrointestinal perforation,and malignancies.
Time frame: From first dose of study drug up to end of study (up to Week 16)
Plasma Concentration of NDI-034858
Plasma concentration of NDI-034858 was measured in participants who received low, medium, or high doses of NDI-034858.
Time frame: Pre-dose, 1 hour post-dose on Day 1 and Week 4, 4 hours post-dose at Week 4, Pre-dose at Week 8, and anytime at Week 12
Participants took part in the study at 45 investigative sites in the United States (US), Germany, Poland, and the Czech Republic from 6 January 2022 to 2 June 2023.
| Milestone | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Started | 75 | 76 | 78 | 76 |
| Completed | 66 | 66 | 65 | 60 |
| Not completed | 9 | 10 | 13 | 16 |
| Withdrew: Adverse event | 1 | 0 | 3 | 5 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 6 | 8 | 6 | 8 |
| Withdrew: Coronavirus disease 2019 (covid-19) | 0 | 0 | 1 | 0 |
| Withdrew: Randomized without dosing due to ineligibility | 0 | 0 | 0 | 2 |
| Withdrew: Reason not specified | 1 | 1 | 1 | 1 |
ACR20 is composite measure defined as improvement of 20 percent(%) from baseline in both number of tender (68) \& number of swollen (66) joints \& a 20% improvement in at least 3 of following 5 criteria: patient global assessment of psoriatic arthritis (PGA-PsA) \[visual analog scale (VAS) where, 0=very good, no symptoms \& 100=very poor, severe symptoms\], physician global assessment of psoriatic arthritis (PhGA-PsA) \[(VAS) where 0=no disease activity \& 100=maximum disease activity\], patient global assessment of psoriatic arthritis pain (PGAAP) \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire i.e., Health Assessment Questionnaire-Disability Index \[HAQ-DI\] (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip \& activities, 0=without difficulty to 3=unable to do) \& acute phase reactant like high sensitivity C-reactive protein \[hsCRP\]). Percentages are rounded off to the nearest decimal.
| percentage of participants | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12 | 29.2 (18.7 to 39.7) | 35.2 (24.1 to 46.3) | 53.3 (42.0 to 64.6) | 54.2 (42.7 to 65.7) |
The ACR-50 is a composite measure defined as improvement of 50% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 50% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \[(VAS) where 0=no disease activity and 100=maximum disease activity\], PGAAP \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire (i.e., HAQ-DI) \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\] and an acute phase reactant \[i.e., erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\]. Percentages are rounded off to the nearest decimal.
| percentage of participants | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Percentage of Participants Who Achieved at Least an ACR-50 Response at Week 12 | 9.7 (2.9 to 16.6) | 15.5 (7.1 to 23.9) | 26.7 (16.7 to 36.7) | 26.4 (16.2 to 36.6) |
The ACR-70 is a composite measure defined as improvement of 70% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 70% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \[(VAS) where 0=no disease activity and 100=maximum disease activity\], PGAAP \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire (i.e., HAQ-DI) \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\] and an acute phase reactant (i.e., ESR or CRP). Percentages are rounded off to the nearest decimal.
| percentage of participants | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Percentage of Participants Who Achieved at Least an ACR-70 Response at Week 12 | 5.6 (1.5 to 13.6) | 8.5 (2.0 to 14.9) | 14.7 (6.7 to 22.7) | 13.9 (5.9 to 21.9) |
The TJC 68 is a total score of points assigned for the presence of tenderness in the 68 joints in the upper body and upper/lower extremity. The response to tenderness for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all tender joints was derived. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.
| tender joints | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in Tender Joint Count (TJC) at Week 12 | -5.9 ± 1.12 | -7.6 ± 1.12 | -8.9 ± 1.12 | -8.3 ± 1.15 |
The SJC 66 (TJC 68 joint assessment minus hip joints, which cannot be assessed for swelling) is a total score of points assigned for presence of swelling in the 66 joints in the upper body and upper/lower extremity. The response to swelling for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all swollen joints was derived. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.
| swollen joints | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in Swollen Joint Count (SJC) at Week 12 | -3.9 ± 0.57 | -4.8 ± 0.58 | -5.0 ± 0.58 | -5.0 ± 0.59 |
Participants assessed their overall disease status based on symptoms of psoriasis and psoriatic arthritis at the time of the visit using the PGA-PsA VAS of 100 millimeters (mm) which ranges from 0 (very good, no symptoms) to 100 (very poor, severe symptoms). A negative change from Baseline indicates improvement in symptoms.
| mm | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in PGA-PsA at Week 12 | -11.1 ± 2.85 | -12.9 ± 2.84 | -20.2 ± 2.85 | -19.8 ± 2.92 |
Participants assessed their overall psoriatic arthritis-related pain at the time of the visit using the PGAAP VAS of 100 mm which ranges from 0 (no pain) to 100 (most severe pain). A negative change from Baseline indicates improvement in pain.
| mm | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in PGAAP at Week 12 | -12.1 ± 2.75 | -13.0 ± 2.74 | -18.8 ± 2.75 | -18.4 ± 2.82 |
The participants' overall disease status was assessed, taking into account signs, symptoms, and function, of all components of joint and skin affected at the time of the visit and this overall status was rated by the investigator using the PhGA-PsA VAS of 100 mm where 0 is 'very good, asymptomatic, and no limitation of normal activities' and 100 is 'very poor, very severe symptoms which are intolerable, and inability to carry out all normal activities'. A negative change from Baseline indicates improvement in symptoms.
| mm | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in PhGA-PsA at Week 12 | -20.7 ± 2.66 | -29.6 ± 2.65 | -31.3 ± 2.65 | -31.6 ± 2.73 |
The HAQ-DI consists of 20 questions referring to eight domains consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 (without any difficulty) to 3 (unable to do). The worst score within each domain will be used as the domain score (i.e., if the score for one question is 1 and 2 for the other, then the worst score for the domain is 2). The HAQ-DI total score is calculated by dividing the sum of the domain scores by the number of non-missing domains. The total score indicates the patient's self-assessed level of functional ability and higher scores indicate worse functional ability. The HAQ-DI total score ranges from 0 to 3. A higher score indicates worse function and greater disability. A negative change from Baseline indicates improved function.
| score on a scale | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in HAQ-DI Total Score at Week 12 | -0.22 ± 0.053 | -0.29 ± 0.053 | -0.32 ± 0.053 | -0.28 ± 0.055 |
Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of total score. DC equals the number of tender fingers and toes (tender score \>0). For participants with dactylitis status absent for all the fingers and toes, the DC is set as 0. The total score range of DC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.
| dactylitis count | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in Dactylitis Count (DC) at Week 12 | -2.1 ± 0.39 | -0.8 ± 0.41 | -2.0 ± 0.47 | -1.9 ± 0.41 |
Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites, divided by the number of sites with non-missing score. The total score ranges from 0 to 6, higher scores indicate greater degree of enthesitis. A negative change from baseline indicates improvement.
| score on a scale | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in Leeds Enthesitis Index (LEI) at Week 12 | -0.9 ± 0.24 | -1.4 ± 0.24 | -1.6 ± 0.24 | -1.0 ± 0.25 |
MDA is a measure to indicate a state of minimal disease activity, and is a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC 68 ≤1; SJC 66 ≤1; Psoriasis area and severity index (PASI) score ≤1 \[The total score ranges from 0 (no disease) to 72 (maximal disease)\] or body surface area (BSA) ≤3%; PGAAP ≤15 \[using VAS on a scale of 0 (no pain) to 100 (serious pain)\]; PGA-PsA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1. Percentages are rounded off to the nearest decimal.
| percentage of participants | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Percentage of Participants With Minimal Disease Activity (MDA) Response at Week 12 | 12.5 (4.9 to 20.1) | 18.3 (9.3 to 27.3) | 28.0 (17.8 to 38.2) | 29.2 (18.7 to 39.7) |
The DAPSA score is a composite score and was calculated using: TJC68, SJC66, PGA-PsA, PGAAP, and hsCRP level (milligram per deciliter \[mg/dL\]). DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. The DAPSA score has a lower bound of 0 and has no upper bound. A higher DAPSA score indicated more active disease activity. A negative change from baseline indicates improvement.
| score on a scale | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 12 | -11.56 ± 1.948 | -15.30 ± 1.946 | -17.99 ± 1.943 | -16.79 ± 1.989 |
PASI-75 is assessed in participants with psoriasis involvement for ≥ 3% of the BSA at Baseline and assesses the extent of involvement and severity of psoriasis. To calculate the PASI, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI-75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease. Percentages are rounded off to the nearest decimal.
| percentage of participants | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Percentage of Participants Who Achieved PASI-75 Response at Week 12 | 15.4 (4.1 to 26.7) | 25.6 (11.9 to 39.3) | 28.3 (15.2 to 41.3) | 45.7 (31.3 to 60.0) |
PhGA-PsO responder is defined as participants 1) who had PhGA-PsO score of 0 or 1 at any given post-baseline visit; and 2) who had at least 2-point improvement from baseline. The PhGA-PsO is measured using a 0 to 4 scale with a 0 meaning clear or a 4 meaning severe. The proportion of participants achieving PhGA-PsO response at Week 12 was calculated and analyzed for participants with a score of at least 2 at baseline. Percentages are rounded off to the nearest decimal.
| percentage of participants | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Percentage of Participants Who Achieved a Physician Global Assessment of Psoriasis (PhGA-PsO) of 0 or 1 and at Least a 2-point Improvement at Week 12 | 15.8 (6.3 to 25.3) | 20.4 (9.6 to 31.1) | 20.6 (10.6 to 30.6) | 32.8 (20.7 to 44.8) |
Adverse Event(AE)=medical occurrence that does not necessarily have a causal relationship with this drug also including clinically meaningful findings in laboratory safety tests,vital signs,weight,and electrocardiogram(ECG).TEAEs=AEs occurring at time of or post study drug dosing until study end.SAE=any medical occurrence at any dose that resulted in death,was life-threatening,required inpatient hospitalization/prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was a congenital abnormality/birth defect,an important medical event.AESIs included Common Terminology Criteria for Adverse Events(CTCAE)Grade≥2 cytopenia,CTCAE Grade≥3 elevation of creatine phosphokinase(CPK)\[clinically significant or not\]defined as CPK\>5xupper limit of normal(ULN),infections,adverse events of abnormal liver function tests,adverse events of renal dysfunction,major adverse cardiovascular events,thromboembolic events,gastrointestinal perforation,and malignancies.
| Participants | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| TEAEs | 39 | 42 | 45 | 56 |
| SAEs | 4 | 4 | 3 | 2 |
| AESIs | 19 | 33 | 22 | 38 |
Plasma concentration of NDI-034858 was measured in participants who received low, medium, or high doses of NDI-034858.
| nanograms per milliliter (ng/mL) | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|
| Day 1: Pre-dose | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| Day 1: 1 Hour | 5.860 ± 7.251 | 25.43 ± 37.21 | 38.32 ± 59.74 |
| Week 4: Pre-dose | 25.26 ± 17.95 | 82.11 ± 74.46 | 187.5 ± 140.9 |
| Week 4: 1 Hour | 33.03 ± 24.05 | 112.8 ± 81.19 | 245.3 ± 184.6 |
| Week 4: 4 Hours | 46.68 ± 25.85 | 149.5 ± 90.56 | 370.1 ± 178.4 |
| Week 8: Pre-dose | 26.99 ± 21.00 | 78.29 ± 69.37 | 209.4 ± 182.0 |
| Week 12: Any Time | 24.85 ± 20.58 | 66.17 ± 51.81 | 178.2 ± 149.5 |
Collected over From first dose of study drug up to end of study (up to Week 16). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/75 (0%) | 4/72 (5.6%) | 13/72 (18.1%) |
| NDI-034858 Low Dose | 0/76 (0%) | 4/71 (5.6%) | 19/71 (26.8%) |
| NDI-034858 Medium Dose | 0/78 (0%) | 3/75 (4%) | 27/75 (36%) |
| NDI-034858 High Dose | 0/76 (0%) | 2/72 (2.8%) | 35/72 (48.6%) |
| Event | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/72 | 1/71 | 1/75 | 0/72 |
| CellulitisInfections and infestations | 0/72 | 1/71 | 0/75 | 0/72 |
| Coronary artery diseaseCardiac disorders | 0/72 | 1/71 | 0/75 | 0/72 |
| Respiratory tract infectionInfections and infestations | 0/72 | 1/71 | 0/75 | 0/72 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/72 | 0/71 | 0/75 | 0/72 |
| Bell's palsyNervous system disorders | 0/72 | 0/71 | 0/75 | 1/72 |
| Oesophageal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/72 | 0/71 | 0/75 | 0/72 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/72 | 0/71 | 0/75 | 0/72 |
| PharyngitisInfections and infestations | 0/72 | 0/71 | 0/75 | 1/72 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 1/72 | 0/71 | 0/75 | 0/72 |
| Event | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/72 | 8/71 | 3/75 | 7/72 |
| NasopharyngitisInfections and infestations | 3/72 | 6/71 | 7/75 | 7/72 |
| Aphthous ulcerGastrointestinal disorders | 0/72 | 0/71 | 1/75 | 6/72 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 0/72 | 0/71 | 2/75 | 6/72 |
| HeadacheNervous system disorders | 3/72 | 2/71 | 6/75 | 4/72 |
| RashSkin and subcutaneous tissue disorders | 0/72 | 3/71 | 6/75 | 4/72 |
| Dermatitis allergicSkin and subcutaneous tissue disorders | 0/72 | 1/71 | 1/75 | 4/72 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 4/72 | 0/71 | 2/75 | 1/72 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/72 | 0/71 | 2/75 | 4/72 |
| Rash papularSkin and subcutaneous tissue disorders | 0/72 | 1/71 | 3/75 | 4/72 |
Full Analysis Set included all randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose | Total |
|---|---|---|---|---|---|
| Mean | 49.7 ± 11.83 | 48.3 ± 10.43 | 52.5 ± 12.15 | 49.0 ± 11.51 | 49.9 ± 11.56 |
| Sex: Female, Male(Participants) | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose | Total |
|---|---|---|---|---|---|
| Female | 37 | 40 | 46 | 43 | 166 |
| Male | 35 | 31 | 29 | 29 | 124 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 4 | 2 | 9 |
| Not Hispanic or Latino | 70 | 69 | 71 | 70 | 280 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose | Total |
|---|---|---|---|---|---|
| White | 69 | 66 | 71 | 69 | 275 |
| Non-white | 1 | 3 | 4 | 3 | 11 |
| Missing | 2 | 2 | 0 | 0 | 4 |
| Height(centimeters (cm)) | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose | Total |
|---|---|---|---|---|---|
| Mean | 170.3 ± 10.65 | 170.1 ± 8.67 | 169.0 ± 9.04 | 170.4 ± 9.06 | 169.9 ± 9.35 |
| Weight(kilograms (kg)) | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose | Total |
|---|---|---|---|---|---|
| Mean | 86.26 ± 25.307 | 86.97 ± 26.611 | 85.85 ± 22.048 | 87.74 ± 20.152 | 86.69 ± 23.529 |
| Body Mass Index (BMI)(kilograms per meter square (kg/m^2)) | Placebo | NDI-034858 Low Dose | NDI-034858 Medium Dose | NDI-034858 High Dose | Total |
|---|---|---|---|---|---|
| Mean | 29.48 ± 6.865 | 29.78 ± 8.153 | 30.04 ± 7.937 | 30.15 ± 6.610 | 29.87 ± 7.390 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2022 to primary completion in May 2023, 15 months.
Results were first posted in May 2024, 1 year after primary completion.
Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zasocitinib